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Abstract Peripartum cardiomyopathy (PPCM) is a rare and
life-threatening disease that affects young women in the last
month of pregnancy or within 5 months of delivery. It is a
form of dilated cardiomyopathy with left-sided systolic
dysfunction. The incidence rate in the Western world is
estimated to be 1:3000. Symptoms of PPCM vary greatly and
may be obscured by common physiological aspects of
pregnancy. Therefore, the incidence rate might be higher.
Echocardiography or MRI can confirm or rule out PPCM.
Unfortunately, there is no specific risk factor profile available.
The clinical course varies from complete recovery to
deterioration of cardiac function. Patients with PPCM,
especially those whose ventricular function has not returned
to normal, are advised against further pregnancy. Recently,
more disease-specific therapeutic strategies have been devel-
oped with promising results for prolactin blockade by
bromocriptine. Increasing awareness for PPCM among
general practitioners, gynaecologists and cardiologists may
help to diagnose patients efficiently in order to start adequate
treatment. A national registry is warranted to identify risk
factor profiles and to optimise treatment strategies.
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Introduction
Peripartum cardiomyopathy (PPCM) is a rare and life-
threatening form of dilated cardiomyopathy with left
ventricular systolic dysfunction that affects women in late
pregnancy or in the early puerperium. The incidence of
PPCM is not known. Patients with PPCM, especially those
whose ventricular function has not normalised, are advised
against future pregnancies.
Recently, case reports of young patients with PPCM
have been published in the Netherlands Heart Journal [1, 2].
This review provides an overview of the clinical manifesta-
tion, management, risk factors and potential pathophysiolog-
ical mechanisms of PPCM and emphasises the need for a
national database.
Definition
Peripartum cardiomyopathy was first described in 1849 by
Richie and Virchow but was not recognised as a distinct
clinical entity until 1937 [3]. It is a form of dilated
cardiomyopathy with left ventricular systolic dysfunction
which may lead to symptoms and signs of heart failure.
Based on a report from the National Heart, Lung and Blood
Institute, PPCM is defined by the following four criteria [4]:
1. Development of cardiac failure in the last month of
pregnancy or within 5 months of delivery;
2. Absence of an identifiable cause of cardiac failure;
3. Absence of recognisable heart disease prior to the last
month of pregnancy;
4. Left ventricular systolic dysfunction demonstrated by
echocardiographic criteria, such as left ventricular
ejection fraction.
These criteria limit the diagnosis to the last gestational
month and the first 5 months after delivery and are based
on data obtained in a relatively small group of women
diagnosed in one centre in an earlier diagnostic era. Later
reports describe patients who presented with cardiomyop-
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our own observations, some patients present with clear
PPCM symptoms earlier than the last gestational month.
Therefore, modification of the first criterion might be
necessary. In addition to these criteria, it is recommended
that other conditions, which may be associated with heart
failure in the puerperium, are excluded before the diagnosis
of PPCM is considered. These other conditions include
infectious, toxic or metabolic disorders, underlying valvular
or ischaemic heart disease. However, in clinical practice, it
remains difficult to distinguish patients with pre-existing
(asymptomatic) cardiomyopathy, progressing during preg-
nancy and labour, from actual PPCM patients.
Epidemiology
The real incidence of PPCM is not known. The incidence
varies among geographical regions. An accepted incidence
is 1 in 3000 to 1 in 4000 live births in the United States, 1
in 1000 in South Africa and 1 case per 6000 live births in
Japan [7, 8]. In Haiti, the incidence has been reported to be
as high as 1 in 400 live births and in parts of Nigeria 1 in
100 [9]. As the incidence in the Netherlands is not known,
we have the intention to establish a national database in
order to gain more insight into the epidemiology.
Risk Factors
Several risk factors have been proposed for the develop-
ment of PPCM. They are too widely distributed in the
maternal population to allow for screening. PPCM can
occur at any age but generally occurs in women over the
age of 30 years. It is thought to be more prevalent in
multiparous women, pregnancies with multiple foetuses,
women of African descent and in women receiving long-
term tocolytic therapy (with β-adrenergic agonists). Other
possible risk factors include toxaemia of pregnancy,
maternal cocaine abuse and nutritional deficiencies.
Finally, a history of pre-eclampsia, eclampsia or gesta-
tional hypertension is also thought to be associated with
PPCM [9].
Pathogenesis
The pathogenetic mechanisms of PPCM have been
difficult to study as their incidence and prevalence are
too low in Western countries to allow meaningful
evaluations. Therefore, the pathogenesis is poorly under-
stood. PPCM probably develops due to a complex
interaction of inflammation, haemodynamic stress during
pregnancy and genetic factors. A number of contributing
factors are elucidated in more detail.
Inflammatory Disease
A number of investigators have suggested myocarditis as a
cause of PPCM, although the presence of documented
myocarditis varies considerably within studies. This is
partly related to the timing of the endomyocardial biopsy.
The incidence of inflammation is higher in patients
biopsied earlier after initial presentation. Furthermore, the
criteria applied in diagnosing myocarditis are not congruent
between studies [10–12]. The percentages of virus detected
in endomyocardial biopsies of PPCM patients varied from
10% to 70%, with a similar incidence in controls,
suggesting no specific role for viral infection in the
aetiology of PPCM [10–12]. It is worth noting that
Bultmann reported that the presence of viral genomes in
endomyocardial biopsies was associated with inflammatory
cardiomyopathies exclusively in PPCM patients but not in
control subjects [10]. Experimental data in mouse studies
suggested that encephalomyocarditis viral infection
increases the severity of myocardial damage in postpartum
mice in comparison with nonpregnant control mice.
Primary viral infection, usually in childhood, can lead to a
latent lifelong viral persistence, which is of no pathogenetic
significance. During pregnancy, the immune defence is
impaired. As a consequence, the virus can be reactivated,
leading to more severe viral infections [10].
Abnormal Immune Response
A maternal immunological response to a foetal antigen has
been proposed as another potential aetiology of PPCM.
During pregnancy, foetal cells cross the placenta into the
maternal circulation. The foetal cells are not destroyed
because of the depressed immunological state in the mother
during pregnancy and due to the weak immunogenicity of
the paternal haplotype of the chimeric cells [13]. If these
cells lodge in the cardiac tissue, they can trigger a
pathological autoimmune response. This immune response
can be exacerbated by previous exposure to paternal
antigens through prior pregnancies. PPCM is indeed
associated with high titres of autoantibodies against certain
cardiac tissue proteins [13–15]. As in other forms of heart
failure, inflammatory cytokine levels are significantly
elevated in patients who died of PPCM compared with
survivors [15]. At present, it is unclear whether the
autoimmune response plays a causal role in the develop-
ment and progression of PPCM or whether it should be
considered as a consequence of the disease.
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During pregnancy, labour and delivery, many haemody-
namic changes occur. These alterations begin during the
first 5 to 8 weeks of pregnancy and reach their peak in the
late second trimester. The haemodynamic alterations during
pregnancy include an increase in blood volume and cardiac
output, while systemic vascular resistance decreases.
During labour and delivery, haemodynamic fluctuations
can be profound. Stroke volume increases, and as a
consequence, cardiac output will increase. Blood loss and
anaemia during delivery can further compromise the
haemodynamic state. The haemodynamic changes during
the postpartum state are mainly due to uterine contractions
and relief of caval vein compression. The cardiovascular
changes return to baseline within 3 to 4 weeks following
delivery but may not resolve completely until week 12 after
delivery. Following pregnancy, there is a physiologically
rapid reversal of cardiac hypertrophy, possibly related to
preload reduction [16].
Apoptosis
Myocyte apoptosis has been thought to be a critical
component in the pathological mechanisms driving PPCM
and has been investigated in mice studies. Apoptotic loss of
myocardial cells itself can increase haemodynamic stress
through ventricular dilation and wall thinning. Therefore, it
seems to play an important role in the reduction of cardiac
function and leads ultimately to heart failure. A reduction of
apoptosis in mice leads to less cardiac dysfunction and
reduces mortality. However, complete recovery of cardiac
function has been observed in PPCM patients. Therefore,
the role of cardiomyocyte loss as a general key factor of
PPCM pathophysiology seems unlikely, since regeneration
of myocardial cells is limited [17].
Genetic Factors
There may be a genetic basis for the development of
PPCM. The development of PPCM in two sisters, which
was published in a recent case report, suggests that
women with a positive family history of PPCM may
have an increased risk for the development of this
disease [18]. Furthermore, a current investigation in the
Netherlands suggests that a subset of PPCM is an initial
manifestation of familial dilated cardiomyopathy. There-
fore, presymptomatic screening is suggested for covert
dilated cardiomyopathy in first-degree family members of
PPCM patients who do not show full recovery of cardiac
function. In addition, extensive monitoring in the puerpe-
rium of first-degree family members of patients with
PPCM is advised [19].
Cardioprotective Pathways During Pregnancy
Pregnancy is a physiological state associated with enhanced
oxidative stress related to high metabolic turnover and
elevated tissue oxygen requirements. During pregnancy, the
heart develops a reversible physiological enlargement in
response to mechanical stress and increased cardiac output.
In order to protect the heart, activation of the STAT3
pathway is necessary. STAT3 promotes myocardial angio-
genesis and can mediate cardiomyocyte hypertrophy. In
addition, STAT3 is involved in protection of the heart from
pregnancy-induced oxidative stress by inhibition of the
reactive oxygen species by upregulation of mangenase
superoxide dismutase (MnSOD). Recently, an article was
published in which STAT3 knockout (KO) mice showed
normal pregnancy-induced vessel growth and hypertrophy
but displayed increased apoptosis, loss of myocardial
capillaries, fibrosis and dilatation in postpartum period
[20]. The STAT3 pathway is activated by prolactin, which is
produced by the pituitary gland. Prolactin exists in a full-
length 23-kDa form, which can be cleaved by the protease
cathepsin D into an antioangiogenic and proapoptotic 16-kDa
fragment (Fig. 1). A recent investigation demonstrated the
unfavourable influence of 16-kDa prolactin. Systemic infu-
sion of 23-kDa prolactin in wild-type mice and STAT3 KO
mice had no adverse effects on the heart. However,
expression of the 16-kDa prolactin in the heart destroyed
the cardiac microvasculature, reduced the cardiac function
(in vivo) and decreased the cardiomyocyte metabolism, even
in absence of pregnancy. A recent study showed that
bromocriptine inhibits 23-kDa prolactin. Thereby, it elimi-
nates the substrate for the generation of 16-kDa prolactin and
prevents PPCM in STAT3-KO mice [20].
Diagnosis and Clinical Presentation
Patients with PPCM present with typical signs and
symptoms of left ventricular failure. Owing to the similarity
with normally occurring pregnancy-associated complaints,
the symptoms of PPCM are often misinterpreted, which
prolongs the time lag for diagnosis and the correct
treatment. The delay in reaching the correct diagnosis has
been estimated from weeks to months in approximately
30% of the cases [21]. Normal pregnancies are often
associated with non-specific fatigue, pedal oedema, inabil-
ity to lay supine and decreased exercise capacity. Symp-
toms that should raise suspicion of cardiac failure include
nocturnal cough, orthopnoea, paroxysmal nocturnal
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gitation and haemoptysis [6].
Physical Examination
Physical examination of pregnant women often reveals
peripheral oedema. Most pregnant women have audible
physiological systolic murmurs, created by augmented
blood flow. Patients with PPCM may display signs of
cardiac enlargement, a third heart sound (S3) and murmurs
of mitral and tricuspid regurgitations.
Differential Diagnosis
The differential diagnosis of PPCM includes anaemia,
thyroid disorders, accelerated hypertension, diastolic dys-
function, myocardial infarction, sepsis, severe pre-
eclampsia, amniotic fluid embolism and pulmonary embo-
lism [22]. Pulmonary embolism is an important differential
diagnosis as it is the leading cause of maternal death. In
both cases, the progression of symptoms is rapid and can
lead to death in a short time after the initial presentation.
However, management differs substantially.
Diagnostic Procedures
When a diagnosis of PPCM is suspected, every effort must
be made to exclude pre-existing cardiac disease or other
underlying disorders. A detailed history is the most important
tooltodistinguish a pre-existentcardiomyopathy withPPCM.
Establishing a specific cause for left ventricular failure
excludes the diagnosis of PPCM. An electrocardiogram and
an echocardiogram should be performed in all patients
suspected of PPCM. In addition, a MRI can be used.
Electrocardiogram
An ECG may act as an initial screening tool but is not
suitable for an unambiguous diagnosis of PPCM. Possible
ECG findings include sinus tachycardia and non-specific
ST and T wave abnormalities. In addition, voltage abnor-
malities, such as low voltage or oppositely left ventricular
hypertrophy, can be seen. Q waves are occasionally present
in the anterior leads. Finally, P-R and QRS intervals may be
prolonged. However, it is important to state that a normal
ECG does not exclude PPCM [6].
Echocardiogram
An echocardiogram appears to be extremely valuable in
diagnosing PPCM. Echocardiography can give vital infor-
mation concerning left and right ventricular systolic and
diastolic function. In normal pregnancy, despite increased
left ventricular volume and dimension, most echocardio-
graphic characteristics of left ventricular function, such as
ejection fraction, fractional shortening and contractility, are
similar to nonpregnant women [23]. In contrast, an
Fig. 1 Development of PPCM.
In the absence of cardiomyocyte
STAT3 activity, the amount of
MnSOD will decrease. This
leads to an increase of oxidative
stress and the release of cathep-
sin D, which processes 23-kDa
prolactin into the 16-kDa form.
The 16-kDa prolactin induces
endothelial cell apoptosis, capil-
lary dissociation, vasoconstric-
tion and impairs cardiomyocyte
metabolism, thereby promoting
PPCM. Accordingly, bromo-
criptine, a pharmacological in-
hibitor of prolactin release,
prevents PPCM by inhibiting
23-kDa prolactin. cD cathepsin
D, ROS reactive oxygen species,
MnSOD manganese superoxide
dismutase
Neth Heart J (2011) 19:126–133 129echocardiogram in PPCM usually reveals enlargement of
all four chambers, with marked reduction in left ventricular
systolic function. Small to moderate pericardial effusion
and mitral and tricuspid regurgitation (secondary to
ventricular dilatation) may also be evident [6, 9].
MRI
Cardiac MRI is safe, free of radiation, and offers a global
view of the myocardium. Cine MRI gives a reproducible
and reliable evaluation of the global and segmental
myocardial contraction. Recently, Mouquet et al. investi-
gated eight patients who were diagnosed with PPCM. The
patients did not exhibit a specific cardiac MRI pattern and
importantly no myocardial late enhancement, as is often
seen in idiopathic dilated cardiomyopathy. Therefore,
myocardial fibrosis was thought not to play a major limiting
role in cardiac recovery after PPCM [24]. However, MRI
with delayed enhancement can detect large areas with
cardiac fibrosis but is not sensitive enough to detect
interstitial fibrosis. In addition, due to the small sample
size, incorrect nomenclature and the lack of standardisation
of cardiac magnetic resonance protocols, a large prospec-
tive and systematic study of the prognostic value of fibrosis
in PPCM is necessary.
Serum Markers
As in most forms of heart failure, case reports have
documented that serum levels of troponin T and creatine
kinase are hardly increased in patients with PPCM. BNP
levels in pregnancy are approximately twofold increased
and do not significantly fluctuate during pregnancy. The
rise in BNP level is seen as early as the first trimester and
may persist up to the 24th week after delivery [25]. INF-γ
(a marker of inflammation), prolactin and oxidised LDL
(marker for oxidative stress) are significantly elevated in
PPCM patients in comparison with healthy pregnant
women [26]. Reversal of these parameters predicted a
better outcome. These results suggest that a specific
prognostic biomarker profile may exist in PPCM patients,
which might be used for diagnosis and risk stratification in
the future.
Endomyocardial Biopsy
The role of routine endomyocardial biopsy in the diagnosis
of PPCM is controversial and not standard practice. There
is an inherent risk of perforation and cardiac tamponade
[27].
Treatment
Treatment of PPCM is rather similar to other types of
congestive heart failure. However, concerns regarding the
adverse effects of this therapy for the mother, foetus or
breastfeeding infant may complicate the management of
patients with PPCM. Murali et al. reviewed that conven-
tional pharmacological therapy with diuretics, sodium
restriction, β-blockers, digoxin and afterload reduction
forms the cornerstone of therapy. Angiotensin-converting
enzyme (ACE) inhibitors are absolutely contraindicated
during the second and third trimester of the pregnancy
because of the risk of kidney disturbances of the foetus and
oligohydramnion. Use of ACE inhibitors in breastfeeding
patients is also not recommended [3].
Antithrombotic Therapy
Pregnancy is accompanied by physiological changes in
coagulation that may have evolved to protect women from
the bleeding risk of miscarriage and birth. Many of the
clotting factors increase and anticoagulation factors decrease.
This augmented coagulation and decreased fibrinolysis,
together with the increased risk for ventricular thrombi as a
result of depressed cardiac function, emphasises that PPCM
patients have an increased risk for thromboembolic events.
Warfarin is contraindicated in pregnancy. It crosses the
placenta and is associated with teratogenic effects in the
foetus. However, most of these effects occur particularly
between the 6th and 12th weeks of gestation. As a
consequence, warfarin can be used safely during the third
trimester, the moment most PPCM patients are being
diagnosed. However, warfarin is a long-acting anticoagulant;
therefore, its effect could lead to haemorrhagic complications
in the newborn, or in pregnant patients with preterm delivery
or in need of emergent caesarean section. In comparison, the
short half-life of heparin allows it to be discontinued prior to
delivery to prevent maternal haemorrhage. Heparin is a large
molecule, so it does not cross the placenta and does not cause
teratogenic effects. Hence, subcutaneous heparin is the drug
of choice for the pregnant PPCM patient. For the postpartum
patient, either heparin or warfarin may be used safely. Neither
drug is secreted into breast milk; therefore, the infant is not at
risk of an anticoagulated state [3].
Arrhythmias
Ventricular arrhythmias should be managed aggressively.
Beta-blocking agents are effective in preventing ventricular
arrhythmias. In addition, the use of class III antiarrhythmic
drugs, such as sotalol and amiodarone, can also be
130 Neth Heart J (2011) 19:126–133considered. However, these drugs have many side effects
during chronic use, and these should be carefully weighed
before they are prescribed. Amiodarone may be toxic for
mother and baby, leading to hyperthyroidism and retarded
growth, with the risk of perinatal death. Patients with
symptomatic ventricular arrhythmias may be candidates for
defibrillator implantation (ICD). However, it seems better
to await the recovery of cardiac function because the
disease process is potentially reversible [3].
Bromocriptine
A recent small study investigated the role of bromocriptine in
women with a subsequent pregnancy. A total of 12 pregnant
women who suffered from PPCM in a previous pregnancy
were divided into two groups. Six patients were given
bromocriptine in addition to standard heart failure therapy.
All of these patients had an uneventful post-pregnancy
follow-up. In contrast, all patients in the group who only
received standard heart failure therapy suffered from recur-
rence of PPCM. Furthermore, three patients in the non-
bromocriptine group died [20]. In addition, case reports
confirm recovery of the heart in patients with PPCM who
were treated with bromocriptine in addition to heart failure
therapy. Controlled randomised studies are awaited to
provide evidence for this promising novel therapy. However,
there are case reports on myocardial infarction due to
thromboembolic events in postpartum patients, which
occurred in association with taking bromocriptine [28].
Therefore, it is recommended that bromocriptine should
only be applied in combination with low-dose heparin.
Mechanical Circulatory Support and Heart
Transplantation
Aggressive life-support measures, such as ventricular assist
devices, should be used when more conservative therapy is
not adequate to sustain life, until cardiac recovery occurs
[2, 3]. Heart transplantation should only be considered if
the heart does not recover, and this may take considerable
amount of time.
Prognosis
A number of studies have evaluated the outcome of women
with PPCM and vary with regard to maternal prognosis. In
approximately two thirds of the PPCM patients, improvement
of the left ventricular function was seen on echocardiogram,
and 45% of the patients returned to a normal ejection fraction
(EF>50%)[10, 29]. In contrast, 10% of the patients required
heart transplantation [29]. Recent studies by Mielniczuk et
al. and Brar et al. revealed mortality rates of 2.1% and 3.3%
[30, 31]. This is substantially lower than the 32% 6-month
mortality reported by Sliwa et al. in their series from South
Africa [32]. The variability in mortality may be related to
improvement in medical therapy for heart failure and the
more liberal use of mechanical circulatory support. Despite
these encouraging statistics, a small subset of women
remains whose illness follows a rapid and irreversible course
that ultimately leads to persistent left ventricular dysfunction,
chronic heart failure, heart transplantation or premature
death. Even among patients whose resting left ventricular
systolic function normalises, the contractile reserve of the
left ventricle, when challenged with dobutamine, often
remains diminished [33].
Factors that indicate a poor prognosis in PPCM include a
lower left ventricular ejection fraction at 6 months after
delivery, larger left ventricular end-diastolic dimension, age
over 30 years old, African American descent and multi-
parity [3].
Subsequent Pregnancies
Subsequent pregnancies in patients with PPCM are associ-
ated with a significant effect on both maternal and foetal
outcome. Therefore, it is very important to inform all
PPCM patients of the high risk of recurrence of PPCM
during or after a subsequent pregnancy, even if their heart
function seems to have recovered completely.
The incidence of complications is higher in women with
persistent left ventricular dysfunction. In addition, there is
an increased risk of foetal prematurity and foetal loss.
Although the likelihood of maternal death seems to be very
low in women with recovered left ventricular function, a
persistent reduction in left ventricular ejection fraction and
symptomatic heart failure may occur during subsequent
pregnancies. Elkayam et al. investigated PPCM patients
with a subsequent pregnancy. Of the patients whose heart
function seemed to have recovered, 21% developed
symptoms of heart failure in the subsequent pregnancy
versus 44% of patients with impaired systolic function [34].
Recurrent symptomatic heart failure in patients with a
history of PPCM and recovered left ventricular function has
been attributed to a physiological increase in blood volume,
stroke volume and heart rate during pregnancy. These
haemodynamic changes are expected to cause symptomatic
deterioration in patients with persistent subclinical myocar-
dial dysfunction, which may exist even in patients with
apparent recovery of left ventricular function. However, a
significant depression of left ventricular function associated
with subsequent pregnancy suggests that worsening of
symptoms may also be due to the underlying idiopathic
Neth Heart J (2011) 19:126–133 131process responsible for the development of the cardiomy-
opathy in the previous pregnancy [33].
IfapatientwithapreviousPPCMbecomespregnantagain,
β-blockers can be used safely. Beta-1-selective blockers are
preferable, since these agents are less likely to interfere with
β-2-mediated uterine relaxationand peripheralvasodilatation.
After the first trimester of a subsequent pregnancy, ACE
inhibitorsshouldnotbeused[3]. As already mentioned, there
might be a role for bromocriptine in patients with PPCM and
subsequent pregnancies, but this awaits substantiation by
larger trials [20].
Conclusion
Peripartum cardiomyopathy is a rare form of dilated
cardiomyopathy with left ventricular systolic dysfunction
that affects women in late pregnancy or in the puerperium.
The incidence of PPCM is unknown. Basic research
suggests a role for bromocriptine in the prevention of this
potentially fatal disease, but randomised clinical trials are
lacking. We therefore have the intention to start a national
database for PPCM patients. This will be useful for
gathering epidemiological information to determine the
magnitude of the problem. In addition, the database will
serve as a depository for tissue and blood samples to
answer fundamental questions on the pathogenesis. Fur-
thermore, it will allow us to initiate randomised trials to
investigate the optimal treatment for this disease.
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